PubMed:21533811 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_21533811_2_0","span":{"begin":258,"end":298},"obj":"expanded"},{"id":"SS2_21533811_2_0","span":{"begin":300,"end":304},"obj":"abbr"},{"id":"SS1_21533811_2_1","span":{"begin":382,"end":412},"obj":"expanded"},{"id":"SS2_21533811_2_1","span":{"begin":414,"end":417},"obj":"abbr"},{"id":"SS1_21533811_2_2","span":{"begin":445,"end":465},"obj":"expanded"},{"id":"SS2_21533811_2_2","span":{"begin":467,"end":469},"obj":"abbr"},{"id":"SS1_21533811_4_0","span":{"begin":565,"end":578},"obj":"expanded"},{"id":"SS2_21533811_4_0","span":{"begin":580,"end":582},"obj":"abbr"},{"id":"SS1_21533811_4_1","span":{"begin":659,"end":670},"obj":"expanded"},{"id":"SS2_21533811_4_1","span":{"begin":672,"end":674},"obj":"abbr"}],"relations":[{"id":"AE1_21533811_2_0","pred":"abbreviatedTo","subj":"SS1_21533811_2_0","obj":"SS2_21533811_2_0"},{"id":"AE1_21533811_2_1","pred":"abbreviatedTo","subj":"SS1_21533811_2_1","obj":"SS2_21533811_2_1"},{"id":"AE1_21533811_2_2","pred":"abbreviatedTo","subj":"SS1_21533811_2_2","obj":"SS2_21533811_2_2"},{"id":"AE1_21533811_4_0","pred":"abbreviatedTo","subj":"SS1_21533811_4_0","obj":"SS2_21533811_4_0"},{"id":"AE1_21533811_4_1","pred":"abbreviatedTo","subj":"SS1_21533811_4_1","obj":"SS2_21533811_4_1"}],"text":"Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.\nPURPOSE: The aim of this study was to compare the risk of chemotherapy-induced nausea and vomiting (CINV) events for various 5-HT(3) RAs in patients who received moderately (MEC) or highly emetogenic chemotherapy (HEC) by evaluating hospital or emergency department (ED) admissions.\nMETHODS: PharMetrics claims database was used to identify patients diagnosed with breast cancer (BC) who were initiated on cyclophosphamide-based adjuvant chemotherapy or with lung cancer (LC) initiated on carboplatin-based or cisplatin-based chemotherapy between 2005 and 2008. Patients were stratified in two groups: those initiated and maintained on palonosetron versus those treated with any other 5-HT(3) RA regimens in the 6-month post first chemotherapy. Risk for CINV events, identified by ICD-9-CM for nausea, vomiting, and/or dehydration, were estimated using logistic regressions, controlling for age, gender, comorbidity, and total chemotherapy doses or days.\nRESULTS: Of the 4,868 cyclophosphamide-treated BC, 5,414 carboplatin-treated LC, and 1,692 cisplatin-treated LC identified, there were 1,864 BC (38.5%), 1,806 carboplatin-treated LC (33.4%), and 390 cisplatin-treated LC (23.0%) in the palonosetron-only group. Palonosetron-only group had significantly lower probability of CINV events associated with ED/hospital admissions in all three cohorts (3.5% vs. 6.3% in BC, 9.5% vs. 13.8% in carboplatin-treated LC, and 16.4% vs. 22.6% in cisplatin-treated LC, all at p \u003c 0.05). Logistic regressions found palonosetron-only group had significantly lower risk of CINV events (odds ratios = 0.550, 0.653, and 0.689 in BC, carboplatin-treated LC and cisplatin-treated LC, respectively, p \u003c 0.05).\nCONCLUSION: Patients with lung or breast cancer receiving MEC or HEC had significantly lower risk of CINV events associated with hospital/ED admissions if initiated and maintained on palonosetron relative to patients receiving 5-HT(3) RA regimens."}

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T1","span":{"begin":209,"end":482},"obj":"OBJECTIVE"},{"id":"T2","span":{"begin":492,"end":1154},"obj":"METHODS"},{"id":"T3","span":{"begin":1164,"end":1891},"obj":"RESULTS"},{"id":"T4","span":{"begin":1904,"end":2139},"obj":"CONCLUSIONS"}],"text":"Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.\nPURPOSE: The aim of this study was to compare the risk of chemotherapy-induced nausea and vomiting (CINV) events for various 5-HT(3) RAs in patients who received moderately (MEC) or highly emetogenic chemotherapy (HEC) by evaluating hospital or emergency department (ED) admissions.\nMETHODS: PharMetrics claims database was used to identify patients diagnosed with breast cancer (BC) who were initiated on cyclophosphamide-based adjuvant chemotherapy or with lung cancer (LC) initiated on carboplatin-based or cisplatin-based chemotherapy between 2005 and 2008. Patients were stratified in two groups: those initiated and maintained on palonosetron versus those treated with any other 5-HT(3) RA regimens in the 6-month post first chemotherapy. Risk for CINV events, identified by ICD-9-CM for nausea, vomiting, and/or dehydration, were estimated using logistic regressions, controlling for age, gender, comorbidity, and total chemotherapy doses or days.\nRESULTS: Of the 4,868 cyclophosphamide-treated BC, 5,414 carboplatin-treated LC, and 1,692 cisplatin-treated LC identified, there were 1,864 BC (38.5%), 1,806 carboplatin-treated LC (33.4%), and 390 cisplatin-treated LC (23.0%) in the palonosetron-only group. Palonosetron-only group had significantly lower probability of CINV events associated with ED/hospital admissions in all three cohorts (3.5% vs. 6.3% in BC, 9.5% vs. 13.8% in carboplatin-treated LC, and 16.4% vs. 22.6% in cisplatin-treated LC, all at p \u003c 0.05). Logistic regressions found palonosetron-only group had significantly lower risk of CINV events (odds ratios = 0.550, 0.653, and 0.689 in BC, carboplatin-treated LC and cisplatin-treated LC, respectively, p \u003c 0.05).\nCONCLUSION: Patients with lung or breast cancer receiving MEC or HEC had significantly lower risk of CINV events associated with hospital/ED admissions if initiated and maintained on palonosetron relative to patients receiving 5-HT(3) RA regimens."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":279,"end":285},"obj":"HP_0002018"},{"id":"T2","span":{"begin":290,"end":298},"obj":"HP_0002013"}],"text":"Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.\nPURPOSE: The aim of this study was to compare the risk of chemotherapy-induced nausea and vomiting (CINV) events for various 5-HT(3) RAs in patients who received moderately (MEC) or highly emetogenic chemotherapy (HEC) by evaluating hospital or emergency department (ED) admissions.\nMETHODS: PharMetrics claims database was used to identify patients diagnosed with breast cancer (BC) who were initiated on cyclophosphamide-based adjuvant chemotherapy or with lung cancer (LC) initiated on carboplatin-based or cisplatin-based chemotherapy between 2005 and 2008. Patients were stratified in two groups: those initiated and maintained on palonosetron versus those treated with any other 5-HT(3) RA regimens in the 6-month post first chemotherapy. Risk for CINV events, identified by ICD-9-CM for nausea, vomiting, and/or dehydration, were estimated using logistic regressions, controlling for age, gender, comorbidity, and total chemotherapy doses or days.\nRESULTS: Of the 4,868 cyclophosphamide-treated BC, 5,414 carboplatin-treated LC, and 1,692 cisplatin-treated LC identified, there were 1,864 BC (38.5%), 1,806 carboplatin-treated LC (33.4%), and 390 cisplatin-treated LC (23.0%) in the palonosetron-only group. Palonosetron-only group had significantly lower probability of CINV events associated with ED/hospital admissions in all three cohorts (3.5% vs. 6.3% in BC, 9.5% vs. 13.8% in carboplatin-treated LC, and 16.4% vs. 22.6% in cisplatin-treated LC, all at p \u003c 0.05). Logistic regressions found palonosetron-only group had significantly lower risk of CINV events (odds ratios = 0.550, 0.653, and 0.689 in BC, carboplatin-treated LC and cisplatin-treated LC, respectively, p \u003c 0.05).\nCONCLUSION: Patients with lung or breast cancer receiving MEC or HEC had significantly lower risk of CINV events associated with hospital/ED admissions if initiated and maintained on palonosetron relative to patients receiving 5-HT(3) RA regimens."}